UBS maintains Buy on Amgen, raises target to $420

1 min read | Published on 06 Jul 2026, 08:44 PM |Updated on 14 Jul 2026, 02:06 AM

Reviewed by

Radhika SScanX News Team

Key Highlights

UBS analyst Michael Yee maintained a Buy rating on Amgen and raised the price target to $420. This contrasts with Guggenheim, Morgan Stanley, and Cantor Fitzgerald, who hold Neutral or Equal-Weight ratings with lower targets.

*this image is generated using AI for illustrative purposes only.

UBS analyst Michael Yee has maintained a Buy rating on Amgen (NASDAQ: AMGN) while raising the price target from $400 to $420. This adjustment signals confidence in the biopharmaceutical company's growth trajectory and valuation potential. The revised target highlights a more bullish stance compared to recent assessments from other major firms, emphasizing Amgen's capacity to deliver shareholder value.

The update from UBS arrives alongside varied perspectives from other analysts. Guggenheim analyst Vamil Divan has maintained a Neutral rating on Amgen while raising the price target from $340 to $343. This adjustment reflects a dynamic assessment of the company's market position and future earnings potential, acknowledging its ability to navigate current industry conditions.

Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Amgen while lowering the price target from $340 to $333. This adjustment reflects a revised valuation outlook that contrasts with the more bullish sentiment from UBS. Separately, Truist Securities analyst Gregory Renza has maintained a Hold rating on Amgen while raising the price target from $327 to $340, indicating confidence in the stock's near-term trajectory.

Cantor Fitzgerald analyst Carter Gould has reaffirmed a Neutral rating on Amgen, maintaining a price target of $350. The consensus from major firms shows varied perspectives on Amgen's potential, with targets now spanning a wider range due to the UBS update.

Firm	Analyst	Rating	Price Target
UBS	Michael Yee	Buy	$420
Cantor Fitzgerald	Carter Gould	Neutral	$350
Guggenheim	Vamil Divan	Neutral	$343
Truist Securities	Gregory Renza	Hold	$340
Morgan Stanley	Terence Flynn	Equal-Weight	$333

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific catalysts does UBS anticipate will drive Amgen's growth to justify the $420 price target?

How will the divergence in analyst ratings impact institutional investor sentiment toward Amgen?

What upcoming clinical trial results or regulatory decisions could shift the current consensus on Amgen's valuation?

Amgen stock returns 13.3% annually over 15 years

0 min read | Published on 08 Jul 2026, 01:05 AM |Updated on 08 Jul 2026, 01:05 AM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Amgen has delivered an average annual return of 13.3% over the last 15 years, outperforming the market by 1.05% annually. With a current market capitalization of $202.05 billion, a $100 investment made 15 years ago would now be worth $647.28.

*this image is generated using AI for illustrative purposes only.

Amgen has outperformed the market over the past 15 years by 1.05% on an annualized basis, producing an average annual return of 13.3%. The company currently holds a market capitalization of $202.05 billion. This performance highlights the impact of compounded returns on long-term cash growth.

Investment Growth Analysis

An investor who purchased $100 of Amgen stock 15 years ago would see that investment grow to $647.28 today. This valuation is based on a current share price of $374.17.